Form 4: Omada Health Director Julie Klapstein Receives 9,736 Restricted Stock Units

Omada Health, Inc. director Julie D. Klapstein was granted 9,736 restricted stock units (RSUs) on June 5, 2025, which are set to fully vest on the first anniversary of the grant date.

Summary

• Julie D. Klapstein, a Director at Omada Health, Inc. (OMDA), acquired 9,736 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 5, 2025.
• These RSUs were acquired at a price of $0, indicating they were a grant rather than a purchase.
• Following this transaction, Julie D. Klapstein directly beneficially owns 9,736 shares.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting.
• 100% of these RSUs are scheduled to fully vest on the first anniversary of June 5, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns their interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• RSU grants are a common form of equity compensation, indicating standard corporate governance practices for incentivizing board members.

Future Outlook

The future outlook indicates that the 9,736 Restricted Stock Units granted to Director Julie D. Klapstein are scheduled to fully vest on June 5, 2026, which is the first anniversary of the grant date.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries for publicly traded companies. It reflects standard compensation practices for board members, where equity grants are used to align management and director incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a widely accepted practice in corporate governance across various industries, including healthcare technology, to incentivize long-term commitment and performance.
• The vesting schedule of 100% on the first anniversary is a common structure for director RSU grants, similar to practices observed in companies like Teladoc Health (TDOC) or Livongo Health (LVGO, prior to acquisition), which also operate in the digital health space and utilize equity compensation to retain and motivate key personnel.

Related Party Transactions

• The grant of 9,736 Restricted Stock Units (RSUs) to Julie D. Klapstein, a director of Omada Health, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The 9,736 Restricted Stock Units (RSUs) granted to Julie D. Klapstein are expected to fully vest on June 5, 2026.

Key Dates

Keywords

Omada Health, OMDA, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership